Descriptive Study Comparing Regadenoson Versus Dipyridamole in Use as Pharmacological Stress Agent Before a Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (SPECT)

Trial Profile

Descriptive Study Comparing Regadenoson Versus Dipyridamole in Use as Pharmacological Stress Agent Before a Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (SPECT)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2017

At a glance

  • Drugs Dipyridamole (Primary) ; Regadenoson (Primary)
  • Indications Coronary disorders
  • Focus Therapeutic Use
  • Acronyms REDUCE
  • Most Recent Events

    • 11 May 2017 Planned End Date changed from 1 Nov 2017 to 3 Feb 2018.
    • 11 May 2017 Planned primary completion date changed from 1 Oct 2017 to 3 Jan 2018.
    • 11 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top